H.C. Wainwright initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $84 price target The firm says the company has established itself as a “proven commercial execution success story” due to the delivery on its lead asset, Cortrophin Gel, as well as its generics business unit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals presents preclinical data on Purified Cortrophin Gel use
- ANI Pharmaceuticals Highlights Financial Performance Amid Challenges
- ANI Pharmaceuticals Approves Key Proposals at Annual Meeting
- ANI Pharmaceuticals initiates Phase 4 trial of Purified Cortrophin Gel
- ANI Pharmaceuticals Releases May 2025 Financial Presentation